The Technical Analyst
ADC Therapeutics SA [ADCT]
Exchange: NYSE Sector: Healthcare Industry: Biotechnology
ADC Therapeutics SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
4.53% $4.61
America/New_York / 9 mai 2024 @ 12:24
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 381.77 mill |
| EPS: | -2.77 |
| P/E: | -1.660 |
| Earnings Date: | Aug 06, 2024 |
| SharesOutstanding: | 82.81 mill |
| Avg Daily Volume: | 0.620 mill |
| RATING 2024-05-09 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.660 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE -1.660 | industry: PE 40.47 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0414 (-100.90%) $-4.65 |
| Date: 2024-05-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.19 - 5.05 ( +/- 9.22%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-03 | Redmile Group, Llc | Sell | 59 986 | Cash-settled Swaps |
| 2024-02-01 | Redmile Group, Llc | Sell | 19 700 | Cash-settled Swaps |
| 2024-02-01 | Redmile Group, Llc | Buy | 205 483 | Cash-settled Swaps |
| 2024-01-31 | Redmile Group, Llc | Buy | 150 000 | Cash-settled Swaps |
| 2024-01-29 | Redmile Group, Llc | Buy | 150 000 | Cash-settled Swaps |
| INSIDER POWER |
|---|
| -45.64 |
| Last 79 transactions |
| Buy: 1 817 492 | Sell: 5 217 316 |
Forecast:
14:02 - $4.61
Live Trading Signals (every 1 min)
Forecast
1: 12:32 - $4.63
Forecast 2: 13:22 - $4.61
Forecast 3: 14:02 - $4.61
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.61 (4.53% ) |
| Volume | 0.122 mill |
| Avg. Vol. | 0.620 mill |
| % of Avg. Vol | 19.71 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ADCT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ADCT
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Latest Press Releases
2024-05-09 07:15:00 - Press Release
Adc Therapeutics To Participate In 2024 Rbc Capital Markets Global Healthcare Conference
Lausanne, switzerland, may 09, 2024 (globe newswire) -- adc therapeutics sa (nyse: adct) today announced that ameet mallik, chief executive officer, will participate in a fireside chat at the 2024 rbc capital markets global healthcare conference on tuesday, may 14, 2024, at 1:35 p.m. et.
2024-05-06 07:30:00 - Press Release
Adc Therapeutics Announces $105 Million Underwritten Offering Of Common Shares And Pre-funded Warrants
Lausanne, switzerland, may 06, 2024 (globe newswire) -- adc therapeutics sa (nyse: adct) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8,163,265 common shares at a price of $4.812 per pre-funded warrant (being the offering price per common share in the offering minus the exercise price). the gross proceeds from the offering, before deducting the underwriting discount and offering expenses payable by the company and assuming no exercise of the pre-funded warrants, are expected to be approximately $105...
2024-05-06 06:10:00 - Press Release
Adc Therapeutics Reports First Quarter 2024 Financial Results And Provides Business Updates
Zynlonta® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%) 1 compared to 1q 2023
2024-05-06 06:00:00 - Press Release
Adc Therapeutics Announces Initial Data From Investigator-initiated Phase 2 Clinical Trial Of Zynlonta® In Patients With Relapsed/refractory Marginal Zone Lymphoma
Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (mzl) show 13 patients achieved a complete response and one patient achieved a partial response with zynlonta ®
2024-05-01 16:05:00 - Press Release
Adc Therapeutics Makes Grants To New Employees Under Inducement Plan
Lausanne, switzerland, may 01, 2024 (globe newswire) -- adc therapeutics sa (nyse: adct) today announced that the company has made grants of options to purchase an aggregate of 147,600 of the company's common shares to four new employees on may 1, 2024 (each, a “grant”). the grants were offered as material inducement to the employees' employment. the grants were approved by the compensation committee of the company's board of directors pursuant to the company's inducement plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the company. the grants were made in reliance on the employment inducement exemption under the nyse's listed company manual rule 303a...
Latest News
2024-05-09 07:15:00 - GlobeNewsWire
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 1:35 p.m. ET.
2024-05-06 08:21:04 - Zacks Investment Research
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.56 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.74 per share a year ago.
2024-03-13 09:21:06 - Zacks Investment Research
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.30 per share a year ago.
2024-03-06 07:00:00 - GlobeNewsWire
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024, at 8:30 a.m. ET to report financial results for the fourth quarter and year ended December 31, 2023, and provide business updates.
2024-02-20 11:06:46 - Zacks Investment Research
Earnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to Decline
ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-02-15 11:57:01 - InvestorPlace
The 3 Biotech Stocks That Could Make Your February Unforgettable
Following a hot year of M&A with biotech stocks, we'll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between now and 2028, pharmaceutical giants stand to lose billions in revenue as blockbuster drug patents expire.
2024-02-08 13:15:00 - InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
With patience, some of the most undervalued biotech stocks can create massive wealth. Look at ACADIA Pharmaceuticals (NASDAQ: ACAD ), for example.
2024-02-02 21:26:32 - InvestorPlace
The Jobs Report Blows Away Forecasts
2024-01-19 14:06:06 - Zacks Investment Research
ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why
ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.
2024-01-19 10:41:30 - Zacks Investment Research
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
Here is how ADC Therapeutics SA (ADCT) and CytomX Therapeutics (CTMX) have performed compared to their sector so far this year.